CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.64: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.19BCNY771.01M · vs all stocks (USD)
Revenue (TTM)
1.14BCNY169.33M · vs all stocks (USD)
Profit Margin
-1.00%vs Biotechnology peers
Beta
0.6930xvs all stocks
52-Week Change
-21.47%vs all stocks
Market Capitalization
5.19BCNY771.01M · vs all stocks (USD)
Enterprise Value
5.53BCNY821.78M · vs all stocks (USD)
Forward P/E
26.93xvs Biotechnology peers
Price to Sales (TTM)
4.77xvs Biotechnology peers
Price to Book (MRQ)
4.18xvs Biotechnology peers
Enterprise to Revenue
4.85xvs Biotechnology peers
Enterprise to EBITDA
135.89xvs Biotechnology peers
Gross Margin
22.15%vs Biotechnology peers
Profit Margin
-1.00%vs Biotechnology peers
Operating Margin
-5.86%vs Biotechnology peers
Return on Assets (TTM)
-0.20%vs Biotechnology peers
Return on Equity (TTM)
-0.87%vs Biotechnology peers
Revenue (TTM)
1.14BCNY169.33M · vs all stocks (USD)
Revenue per Share (TTM)
2.89CNYUpdated Aug 19, 2026Quarterly Revenue Growth
2.10%vs Biotechnology peers
Gross Profit (TTM)
314.06MCNY46.64M · vs all stocks (USD)
EBITDA (TTM)
167.83MCNY24.93M · vs all stocks (USD)
Net Income (TTM)
-11.39MCNY-1.69M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.96%vs Biotechnology peers
Operating Cash Flow (TTM)
221.72MCNY32.93M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
85.10MCNY12.64M · vs all stocks (USD)
5-Year Average Dividend Yield
0.47%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
24.34MCNYFY2025 · Dec 31, 2025Revenue
1.13BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
810.03MCNYFY2025 · Dec 31, 2025Gross Profit
324.69MCNYFY2025 · Dec 31, 2025Operating Income
39.10MCNY5.81M · vs all stocks (USD)
Pre-tax Income
16.01MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.46MCNYFY2025 · Dec 31, 2025Net Income
13.55MCNYFY2025 · Dec 31, 2025EBIT
31.88MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
167.83MCNYFY2025 · Dec 31, 2025Research & Development
59.84MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
94.98MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.20MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
9.86MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
15.86MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
447.07MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
13.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-140.89KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-12.12MCNYFY2025 · Dec 31, 2025Free Cash Flow
-74.41MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
405.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
13.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
64.68MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-89.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-957.65KCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.29MCNYFY2025 · Dec 31, 2025Purchase of Investments
-21.65MCNYFY2025 · Dec 31, 2025Sale of Investments
60.25MCNYFY2025 · Dec 31, 2025Other Investing Activity
-46.22MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-69.90MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
21.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-47.53MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.90MCNYFY2025 · Dec 31, 2025Other Financing Charges
-50.28MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-79.71MCNYFY2025 · Dec 31, 2025Shares Outstanding
497.96MSharesUpdated Aug 19, 2026Float Shares
287.73MSharesUpdated Aug 19, 2026% Held by Insiders
29.98%vs all stocks
% Held by Institutions
1.03%vs all stocks
Total Cash (MRQ)
464.68MCNY69.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9330CNYUpdated Aug 19, 2026Total Debt (MRQ)
451.10MCNY67.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3440xvs Biotechnology peers
Current Ratio (MRQ)
2.13xvs Biotechnology peers
Book Value per Share (MRQ)
2.58CNYUpdated Aug 19, 2026Total Assets
2.03BCNY301.93M · vs all stocks (USD)
Total Current Assets
765.02MCNYFY2025 · Dec 31, 2025Total Liabilities
732.59MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
377.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
355.45MCNYFY2025 · Dec 31, 2025Cash
405.45MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
411.83MCNYFY2025 · Dec 31, 2025Other Short-term Investments
45.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
229.26MCNYFY2025 · Dec 31, 2025Inventory
9.47MCNYFY2025 · Dec 31, 2025Accounts Payable
50.31MCNYFY2025 · Dec 31, 2025Short-term Debt
135.22MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.02MCNYFY2025 · Dec 31, 2025Long-term Debt
333.95MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.57MCNYFY2025 · Dec 31, 2025Common Stock (Book)
497.96MCNYFY2025 · Dec 31, 2025Retained Earnings
-667.16MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.30BCNY193.13M · vs all stocks (USD)
52-Week Low
7.22CNYUpdated Aug 19, 202652-Week High
14.33CNYUpdated Aug 19, 202652-Week Change
-21.47%vs all stocks
Beta
0.6930xvs all stocks
50-Day MA
9.23CNYUpdated Aug 19, 2026200-Day MA
10.07CNYUpdated Aug 19, 2026Avg 10-Day Volume
59.37MSharesUpdated Aug 19, 2026Avg 30-Day Volume
51.69MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0200CNYUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.64: safe zoneNotable
Altman Z-Score: 4.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Si-Bone Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
MiMedx Group, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
CytomX Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated
Catalyst Pharmaceuticals Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital Elevated